CME Group Valuation
Is CME * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of CME * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: CME * (MX$3501.9) is trading above our estimate of fair value (MX$1574.96)
Significantly Below Fair Value: CME * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CME *?
Other financial metrics that can be useful for relative valuation.
What is CME *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$75.58b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.9x |
Enterprise Value/EBITDA | 20.2x |
PEG Ratio | 7.1x |
Price to Earnings Ratio vs Peers
How does CME *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 29.4x | ||
BOLSA A Bolsa Mexicana de Valores. de | 12.3x | 6.2% | Mex$18.1b |
ICE Intercontinental Exchange | 30.9x | 9.8% | US$76.7b |
MCO Moody's | 43.1x | 11.0% | US$72.6b |
388 Hong Kong Exchanges and Clearing | 31.3x | 8.2% | HK$358.1b |
CME * CME Group | 23.9x | 3.4% | Mex$75.6b |
Price-To-Earnings vs Peers: CME * is good value based on its Price-To-Earnings Ratio (23.9x) compared to the peer average (29.4x).
Price to Earnings Ratio vs Industry
How does CME *'s PE Ratio compare vs other companies in the South American Capital Markets Industry?
Price-To-Earnings vs Industry: CME * is expensive based on its Price-To-Earnings Ratio (23.9x) compared to the South American Capital Markets industry average (8.6x).
Price to Earnings Ratio vs Fair Ratio
What is CME *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 23.9x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CME *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$3,531.54 | Mex$3,792.13 +7.4% | 8.1% | Mex$4,196.08 | Mex$3,138.66 | n/a | 15 |
May ’25 | n/a | Mex$3,894.30 0% | 8.0% | Mex$4,302.78 | Mex$3,218.48 | n/a | 15 |
Apr ’25 | Mex$3,509.00 | Mex$3,752.07 +6.9% | 8.9% | Mex$4,157.88 | Mex$3,076.83 | n/a | 15 |
Mar ’25 | n/a | Mex$3,848.07 0% | 8.8% | Mex$4,263.00 | Mex$3,154.62 | n/a | 15 |
Feb ’25 | Mex$3,548.00 | Mex$3,741.60 +5.5% | 9.5% | Mex$4,216.05 | Mex$3,035.56 | n/a | 15 |
Jan ’25 | n/a | Mex$3,856.16 0% | 8.4% | Mex$4,228.08 | Mex$3,044.21 | n/a | 15 |
Dec ’24 | Mex$3,707.50 | Mex$4,002.93 +8.0% | 8.5% | Mex$4,398.18 | Mex$3,166.69 | n/a | 15 |
Nov ’24 | n/a | Mex$4,050.52 0% | 8.5% | Mex$4,453.08 | Mex$3,206.21 | n/a | 15 |
Oct ’24 | n/a | Mex$3,746.78 0% | 8.6% | Mex$4,392.48 | Mex$3,039.59 | n/a | 14 |
Sep ’24 | n/a | Mex$3,605.87 0% | 10.4% | Mex$4,282.50 | Mex$2,860.71 | n/a | 14 |
Aug ’24 | Mex$3,284.00 | Mex$3,607.50 +9.9% | 10.8% | Mex$4,293.08 | Mex$2,822.62 | n/a | 16 |
Jul ’24 | n/a | Mex$3,525.87 0% | 11.0% | Mex$4,269.30 | Mex$2,732.35 | n/a | 15 |
Jun ’24 | n/a | Mex$3,636.52 0% | 11.5% | Mex$4,425.53 | Mex$2,832.34 | n/a | 14 |
May ’24 | n/a | Mex$3,714.82 0% | 11.4% | Mex$4,511.40 | Mex$2,887.30 | n/a | 14 |
Apr ’24 | n/a | Mex$3,750.08 0% | 11.0% | Mex$4,556.60 | Mex$2,916.22 | Mex$3,509.00 | 16 |
Mar ’24 | n/a | Mex$3,795.68 0% | 11.3% | Mex$4,628.88 | Mex$2,962.48 | n/a | 16 |
Feb ’24 | Mex$3,270.30 | Mex$3,792.53 +16.0% | 11.7% | Mex$4,706.10 | Mex$2,993.08 | Mex$3,548.00 | 16 |
Jan ’24 | Mex$3,270.30 | Mex$4,040.06 +23.5% | 10.8% | Mex$4,866.45 | Mex$3,133.99 | n/a | 17 |
Dec ’23 | n/a | Mex$4,065.15 0% | 11.9% | Mex$5,242.78 | Mex$3,126.25 | Mex$3,707.50 | 17 |
Nov ’23 | n/a | Mex$4,151.42 0% | 12.0% | Mex$5,345.03 | Mex$3,187.22 | n/a | 17 |
Oct ’23 | Mex$4,835.00 | Mex$4,363.76 -9.7% | 11.5% | Mex$5,437.40 | Mex$3,383.27 | n/a | 16 |
Sep ’23 | Mex$4,835.00 | Mex$4,378.71 -9.4% | 11.3% | Mex$5,444.82 | Mex$3,387.89 | n/a | 15 |
Aug ’23 | n/a | Mex$4,490.53 0% | 10.0% | Mex$5,482.86 | Mex$3,411.56 | Mex$3,284.00 | 15 |
Jul ’23 | Mex$4,835.00 | Mex$4,796.62 -0.8% | 10.6% | Mex$5,636.12 | Mex$4,025.80 | n/a | 17 |
Jun ’23 | Mex$4,835.00 | Mex$4,799.03 -0.7% | 11.4% | Mex$5,589.57 | Mex$3,936.32 | n/a | 18 |
May ’23 | n/a | Mex$5,073.36 0% | 11.5% | Mex$5,796.07 | Mex$3,877.65 | n/a | 17 |
Analyst Forecast: Target price is less than 20% higher than the current share price.